AbbVie Wins EU Approval for TEPKINLY in Combination with Lenalidomide and Rituximab
The European Commission has approved AbbVie's TEPKINLY with lenalidomide and rituximab as the first bispecific, chemotherapy-free treatment for Relapsed or Refractory Follicular Lymphoma in the second-line setting.
EU Drug Approval | 07/07/2026 | By News Bureau
EU Approves Sanofi's Cenrifki (Tolebrutinib) for Multiple Sclerosis
The European Commission (EC) has approved Sanofi’s Cenrifki (tolebrutinib) as the first disability-targeting treatment for adults with Secondary Progressive Multiple Sclerosis (SPMS) without relapses.
EU Drug Approval | 25/06/2026 | By News Bureau | 135
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy